A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Single (Part 1) and Multiple (Part 2) Ascending Dose Study to Evaluate the Safety, Tolerability, PK and PD of M281 Administered to Healthy Volunteers

Trial Profile

A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Single (Part 1) and Multiple (Part 2) Ascending Dose Study to Evaluate the Safety, Tolerability, PK and PD of M281 Administered to Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs M 281 (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions
  • Sponsors Momenta Pharmaceuticals
  • Most Recent Events

    • 14 Nov 2017 Status changed from recruiting to completed.
    • 02 Aug 2017 According to a Momenta Pharmaceuticals media release, the company expects to complete the multiple ascending dose portion of the study in August 2017.
    • 21 Feb 2017 According to a Momenta Pharmaceuticals media release, the company plans to report the full data from the single and multiple ascending dose portions of the study in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top